# Milestone Pharmaceuticals to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
Canonical URL: https://biopharmsignal.com/news/MIST/milestone-pharmaceuticals-to-present-at-the-h-c-wainwright-4th-annual-bioconnect-investor-conference-at-nasdaq
Ticker: MIST
Company: Milestone Pharmaceuticals Inc.
Source: Milestone Pharmaceuticals Inc.
Published: 2026-05-14 12:30 EST
Original Source URL: https://investors.milestonepharma.com
## Summary

MONTREAL and CHARLOTTE, N.C., May 14, 2026 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that management will present at the  H.C.

## Article Body
MONTREAL and CHARLOTTE, N.C., May 14, 2026 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that management will present at the  H.C.
## Recent Company News
- 2026-05-14 12:30 EST — [Milestone Pharmaceuticals to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ](https://biopharmsignal.com/news/MIST/milestone-pharmaceuticals-to-present-at-the-h-c-wainwright-4th-annual-bioconnect-investor-conference-at-nasdaq) — Source: Milestone Pharmaceuticals Inc.
- 2026-05-13 11:11 EST — [Milestone Pharmaceuticals Announces First Quarter 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/MIST/milestone-pharmaceuticals-announces-first-quarter-2026-financial-results-and-provides-corporate-update) — Source: Milestone Pharmaceuticals Inc.
- 2026-05-06 12:00 EST — [Milestone Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 13, 2026](https://biopharmsignal.com/news/MIST/milestone-pharmaceuticals-to-announce-first-quarter-2026-financial-results-on-may-13-2026) — Source: Milestone Pharmaceuticals Inc.
- 2026-04-10 12:00 EST — [Milestone Pharmaceuticals Announces RESET-PSVT Registry to Generate Real-World Evidence on CARDAMYST™ (etripamil) Nasal Spray in Patients With PSVT](https://biopharmsignal.com/news/MIST/milestone-pharmaceuticals-announces-reset-psvt-registry-to-generate-real-world-evidence-on-cardamysttm-etripamil-nasal-spray-in-patients-with-psvt) — Source: Milestone Pharmaceuticals Inc.
- 2026-04-07 12:30 EST — [Milestone Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference](https://biopharmsignal.com/news/MIST/milestone-pharmaceuticals-to-present-at-the-25th-annual-needham-virtual-healthcare-conference) — Source: Milestone Pharmaceuticals Inc.
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)